Prestige Consmr Healthcare Inc Stock Price, News & Analysis

Prestige Consumer Healthcare (NYSE:PBH) reported strong financial results for Q4 and fiscal 2025. Q4 revenue reached $296.5M, up 7.0% YoY, with organic growth of 7.9%. Full-year revenue hit $1,137.8M, a 1.1% increase, with organic growth of 1.2%. The company achieved fiscal 2025 diluted EPS of $4.29 and adjusted EPS of $4.52, up 7.4% YoY. Strong performance was driven by International business strength, North American growth across categories, and eCommerce success. GI and Women's Health categories led growth, with notable performance from Summer's Eve, Dramamine, and Fleet brands. The company reduced leverage to 2.4x and repurchased 0.7M shares for $51.5M. For fiscal 2026, PBH projects organic revenue growth of 1-2% and diluted EPS of $4.70-$4.82, despite anticipated $15M headwind from tariff impacts.

Prestige Consumer Healthcare (NYSE:PBH) reported strong financial results for Q4 and fiscal 2025. Q4 revenue reached a record $296.5M, up 7.0% YoY, with organic revenue growth of 7.9%. Full-year revenue was $1,137.8M, a 1.1% increase from FY2024. The company achieved diluted EPS of $4.29 for FY2025, while adjusted EPS grew 7.4% to $4.52. Growth was driven by strong performance in GI and Women's Health categories, led by Summer's Eve, Dramamine, and Fleet brands. The International segment showed robust growth, particularly in Australia with the Hydralyte brand. The company reduced leverage to 2.4x and repurchased 0.7M shares for $51.5M. For FY2026, PBH projects organic revenue growth of 1-2% and diluted EPS of $4.70-$4.82, despite anticipated $15M headwind from inflationary tariff impacts.

Prestige Consumer Healthcare has scheduled its fiscal 2025 fourth quarter and year-end earnings announcement for Thursday, May 8, 2025, before market opening. The company will follow this with a conference call at 8:30 a.m. ET on the same day.

Stakeholders can participate in two ways:

• Through a live Internet webcast accessible via the Investor Relations page at prestigeconsumerhealthcare.com
• Via phone conference by registering online to receive dial-in details and a unique pin

For those joining by phone, it is recommended to connect 10 minutes before the event starts. A replay of the conference call will be available for approximately one week after the event and can be accessed through the company's Investor Relations webpage.

Prestige Consumer Healthcare (NYSE:PBH) reported strong Q3 fiscal 2025 results with revenue reaching $290.3 million, up 2.7% year-over-year. The company achieved record quarterly sales and earnings, with diluted EPS increasing approximately 15% to $1.22.

The performance was driven by strong International business growth, particularly the Hydralyte brand, and sequential improvement in Clear Eyes revenues. The company's net income for Q3 increased to $61.0 million from $53.0 million in the prior year.

The company reduced its leverage to 2.5x and generated strong free cash flow of $63.5 million in Q3. Based on the strong performance, management raised its full-year fiscal 2025 earnings outlook to approximately $4.50 per share, while maintaining revenue guidance of $1,128 to $1,132 million with organic growth of approximately 1%.

Prestige Consumer Healthcare (NYSE:PBH) has announced two important upcoming events. First, the company will release its fiscal 2025 third quarter earnings on Thursday, February 6, 2025, before market opening, followed by a conference call at 8:30 a.m. ET. Investors can join the webcast through the company's Investor Relations webpage or register for phone participation.

Additionally, PBH will participate in a fireside chat at the 27th annual ICR Conference in Orlando, FL on Tuesday, January 14th, at 11:30 a.m. ET. Both events will be accessible via webcast on the company's website, with replays available afterward.

Prestige Consumer Healthcare (NYSE: PBH) has expanded the role of Chief Financial Officer Christine Sacco to include Chief Operating Officer responsibilities, effective immediately. In this enhanced role, Ms. Sacco will oversee the Company's supply chain along with her existing CFO duties. She will continue to report to CEO Ron Lombardi. Lombardi highlighted Sacco's strategic leadership and deep understanding of the business, which have been instrumental in the company's growth over her 8-year tenure as CFO.

Ms. Sacco, a seasoned executive with over 27 years of experience in the consumer products and specialty pharma sectors, has been the CFO since 2016. Her tenure has seen significant contributions to Prestige's strategic transformation and financial success, including strong sales, earnings, and cash flow growth. This expanded role aims to enhance the execution of strategic initiatives and drive operational excellence, positioning Prestige for further organic and M&A growth.

Prestige Consumer Healthcare reported Q2 fiscal 2025 results with revenue of $283.8 million, down 0.9% year-over-year. Diluted EPS increased 2% to $1.09. Net cash from operations grew 13% to $125 million in first six months. The company reduced debt by $75 million and repurchased $38 million in shares year-to-date.

Q2 performance was driven by strong growth in International and Canadian businesses, offsetting Clear Eyes® supply constraints. The company reaffirmed its fiscal 2025 outlook with revenue guidance of $1,125-$1,140 million, organic revenue growth of approximately 1%, and adjusted EPS of $4.40-$4.46.

Prestige Consumer Healthcare Inc. (NYSE:PBH) has announced the release date for its fiscal 2025 second quarter earnings. The company will issue the earnings release on Thursday, November 7, 2024, before the market opens. Following the release, Prestige Consumer Healthcare will host a conference call at 8:30 a.m. ET to discuss the results.

Investors and interested parties can participate in the earnings discussion through two methods:

• A live Internet webcast accessible from the Investor Relations page of www.prestigeconsumerhealthcare.com
• A conference call via phone, with registration required to receive dial-in details and a unique pin

Participants are advised to join 10 minutes prior to the event start. A replay of the conference call will be available for approximately one week on the company's Investor Relations page.

Prestige Consumer Healthcare (NYSE:PBH) has announced its participation in the Barclays Global Consumer Staples Conference on Thursday, September 5, 2024, at 2:15 p.m. ET. The company will present at this significant industry event, offering insights into its operations and strategy.

Interested parties can access a live webcast of the presentation through the company's official website under the 'Investors' section and 'Events and Presentations' tab. For those unable to attend the live event, a replay option will be available on the company's website following the presentation. This announcement highlights Prestige Consumer Healthcare's commitment to investor relations and transparency in its business operations.